Trials / Unknown
UnknownNCT05929248
Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
A Randomized Controlled Trial Aimed at Exploring the Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus Patients With Refractory Thrombocytopenia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Guanmin Gao · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus and refractory thrombocytopenia
Detailed description
This study is a single center, randomized, controlled trial to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus complicated with refractory thrombocytopenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telitacicept | 160mg once a week for 48 weeks |
| DRUG | conventional therapy | Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc. |
| DRUG | Placebo | Used once a week in combination with standard treatment |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2024-06-30
- Completion
- 2024-12-30
- First posted
- 2023-07-03
- Last updated
- 2023-07-03
Source: ClinicalTrials.gov record NCT05929248. Inclusion in this directory is not an endorsement.